Application Information

This drug has been submitted to the FDA under the reference 202343/001.

Names and composition

"JUVISYNC" is the commercial name of a drug composed of SIMVASTATIN and SITAGLIPTIN PHOSPHATE.

Forms

ApplId/ProductId Drug name Active ingredient Form Strenght
202343/001 JUVISYNC SIMVASTATIN; SITAGLIPTIN PHOSPHATE TABLET/ORAL 10MG and EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
202343/002 JUVISYNC SIMVASTATIN; SITAGLIPTIN PHOSPHATE TABLET/ORAL 20MG and EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
202343/003 JUVISYNC SIMVASTATIN; SITAGLIPTIN PHOSPHATE TABLET/ORAL 40MG and EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
202343/004 JUVISYNC SIMVASTATIN; SITAGLIPTIN PHOSPHATE TABLET/ORAL 10MG and EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
202343/005 JUVISYNC SIMVASTATIN; SITAGLIPTIN PHOSPHATE TABLET/ORAL 20MG and EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
202343/006 JUVISYNC SIMVASTATIN; SITAGLIPTIN PHOSPHATE TABLET/ORAL 40MG and EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

Similar Active Ingredient

ApplId/ProductId Drug name Active ingredient Form Strenght
202343/001 JUVISYNC SIMVASTATIN; SITAGLIPTIN PHOSPHATE TABLET/ORAL 10MG and EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
202343/002 JUVISYNC SIMVASTATIN; SITAGLIPTIN PHOSPHATE TABLET/ORAL 20MG and EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
202343/003 JUVISYNC SIMVASTATIN; SITAGLIPTIN PHOSPHATE TABLET/ORAL 40MG and EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
202343/004 JUVISYNC SIMVASTATIN; SITAGLIPTIN PHOSPHATE TABLET/ORAL 10MG and EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
202343/005 JUVISYNC SIMVASTATIN; SITAGLIPTIN PHOSPHATE TABLET/ORAL 20MG and EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
202343/006 JUVISYNC SIMVASTATIN; SITAGLIPTIN PHOSPHATE TABLET/ORAL 40MG and EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

Ask a doctor

A licensed doctor will try to answer your question for free as quickly as possible. Free of charge during the beta period.

Related

Browse by letter
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

© Medications.li 2015-2017 - All rights reserved